DISEASE CHARACTERISTICS:

• Stage IV breast cancer
• Measurable disease

• Progressive disease

  • Increase in disease mass or less than partial response to therapy

  • At least one prior chemotherapy regimen for metastatic disease and progressed

    • Must have received prior therapy with a taxane and an anthracycline
• Estrogen/progesterone receptor-positive patients must have received and progressed on at least one hormonal agent in adjuvant or metastatic setting
• Her2-neu-expressing patients must have received and progressed on trastuzumab (Herceptin®) in adjuvant or metastatic setting
• Prior autologous stem cell transplantation allowed if less than complete response or disease progression in adjuvant or metastatic setting
• Consenting first-degree relative with at least 5 out of 6 HLA-antigen match (may include mismatch at the D locus)

• Hormone receptor status:

  • Estrogen receptor status known
  • Progesterone receptor status known

PATIENT CHARACTERISTICS:

Age:

• 18 to 70

Sex:

• Male or female

Menopausal status:

• Not specified

Performance status:

• Karnofsky 80-100%

Life expectancy:

• More than 6 months

Hematopoietic:

• Not specified

Hepatic:

• Bilirubin ≤ 2 mg/dL
• SGOT < 4 times upper limit of normal
• Hepatitis B surface antigen negative
• Hepatitis C antibody negative

Renal:

• Creatinine ≤ 1.5 mg/dL
• Creatinine clearance ≥ 50 mL/min

Cardiovascular:

• Left ventricular ejection fraction > 45%

Pulmonary:

• DLCO ≥ 50% of predicted

Other:

• HIV negative
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• See Disease Characteristics
• Recovered from prior stem cell transplantation

Chemotherapy:

• See Disease Characteristics

Endocrine therapy:

• See Disease Characteristics
• No concurrent steroids

Radiotherapy:

• Not specified

Surgery:

• Not specified